in some patients resistant to methotrexate received per os. Other reports demonstrate similar effects of methotrexate after oral and parenteral administration (22, 32) . Mter oral administration methotrexate is absorbed quickly, but not completely; reaching its maximum level after 1-2 h. As the oral dose is increased, the amow1t of absorbed drug decreases because of the saturation of the system of carriers responsible for its absorption. The drug administered orally at low doses is completely absorbed, although the' process of absorption can be prolonged by the presence of food in the stomach. The half-life period of methotrexate is triphasic and amowltS to 0.8, 3.5 and 27 h. 50% of the drug binds to proteins, 90% is excreted with urine in an unchanged form in 48 h, as a result of filtration, retrograde tubular resorption and tubular secretion. Small amounts are excreted with bile and faeces, whereas a part is retained in the tissues of the organism (kidneys, liver) bound with dihydrofolate reductase. Using methotrexate, it should be remembered that a minimum proportion of it is metabolised (24 ) . Griseofulvin accelerates its metabolism and may reduce its effect. Salicylates, sulphonamides, phenytoin, diuretic agents belonging to the thiazide group, tetracyclines, chloramphenicol, administered simultaneously with methotrexate, potentiate its effect and also its toxicity (24) . In cases of overdose and onset of toxic symptoms, leucovorin, which is exogenous folic acid, omitting the enzymatic block caused by methotrexate and protecting the patient from poisoning, is administered (24) .
The main route of methotrexate elimination from the system are kidneys. That is why a failure of this organ may lead to an increase of serum level of the drug and considerable aggravation of adverse effects. Thus, monitoring kidney tunction is necessary (28) . Kidney failure can develop as a result of administration of high doses of methotrexate without appropriate hydration of the patient. In rheumatology, however, such high doses are not used.
Clinical Applications
Because of its cytostatic properties, methotrexate has been applied in oncolog)( The main indications for its administration are acute and subacute lymphatic lculcaemia, particularly in children, lymphomas, chorionic epithelioma, sarcomas, spinocellular carcinoma. Besides oncology; methotrexate is also used in dermatology in the trealli1ent of psoriasis, as well as in rheumatology in the treatment of rheumatoid arthritis (6, 25, 44) .
Rheumatoid arthritis (RA) is an autoimmune disPteridines / Vol. 10 / :-..io. 3 ease of unknown aetiology, characterised by inflammation of the synovial membrane of symmetrical joints, causing bone erosions and sometimes affecting other systems. Extraarticular symptoms of rheumatoid arthritis can involve subcutaneous tissue, blood vessels, nervous system, heart, organ of vision. Additionally, enlargement of lymph nodes and spleen can be observed.
In most cases the course of rheumatoid arthritis is chronic with alternating periods of aggravation and remission. Untreated, the disease leads to progressive damage of joints, their deformation, impairment of locomotor fimctions. At present complete cure or prevention of rheumatoid arthritis is impossible. Optimal treatment requires early diagnosis and instituting at an appropriate moment pharmacological treatment preventing the damage of joints (25, 31, 44) . The principal ain1 of the therapy is to obtain a complete remission, but such effect is obtained only in a small number of cases.
Methotrexate is a drug deserving special attention in pharmacological treatment of rheumatoid arthritis. Its administration should be considered in all cases when despite the treatment with non-steroid anti-inflammatory agents the disease remains active. Non-steroid anti-inflammatory agents and corticosteroids, which are also used in the treatment of rheumatoid arthritis can alleviate the discomfort, but do not prevent the damage of joints. Methotrexate, like other agents belonging to the group of drugs modifying the course of rheumatoid arthritis, slows down the process of joint damage or diminishes its effects, preserves the integrity and function of the joints (25, 31 ) . The above group, besides methotrexate, includes hydrm .. ),chloroquine, sulphasalazine, auric salts, D-penicillamine, azathiopirin and cyclosporin A (26) .
In the treatment of rheumatoid arthritis the appropriate moment of instimtion of a drug modifying the course of the disease, e.g. methotrexate, is essential. The interval between diagnosis and administration of such dmgs should not exceed three months, because active rheumatoid arthritis can lead to irreversible destructive changes in the joints as early as the first months of the disease. The choice of a particular drug is influenced by numerous factors such as convenient schedule, required control investigations, period of time atter which a clinical effect is obtained, as well as incidence and type of possible adverse effects. Taking these criteria into consideration, methotrexate is the drug of choice particularly in the severe forms of the disease, i.e. with the rheumatoid factor present, erosions or extraarticular changes.
There have been numerous reports and experimental studies confirming the efficacy of methotrexate as a drug modifYing the course of rheumatoid arthritis. Both experimental studies and clinical observations confirm that administration of low doses of the drug once a vl eek slows dow n the course of the disease, mving to which bone erosions are fcmned later, which is associated with delaying the development of joint damage (29, 30, 42, 44, 46) .
Methotrexate is most frequently used as the only drug modif}'ing the course of rheumatoid arthritis. However, there may be a group of patients in which, despite the administration of the drug and lack of side effects, no improvement of the general conditions and remission of the disease is observed. In such cases the dose of the drug can be increased, methotrexate can be withdrawn and replaced with other drug modi tying the course of the disease, or continued within the framework of combined therapy with other drugs, e.g. azathioprin, sulphalazine (19, 20 ) or cyclosporin (14, 27, 50) . The results of experimental studies and clinical obselTations confirm that in many cases combined therapy is more effective than monotherapy. Untc)l·tunately, it is associated w ith more frequent and severe adverse effects, which necessitates more intensive monitoring and more frequent check-ups of the patients condition.
With methotrexate used as a drug moditying the course of rheumatoid artl1ritis, the duration of the therapy is important. The paticnt should be infc)rmed that tl1e first effects of improvement of his condition will be visible 1-2 months after starting the treatment. Also tl1C period of nlrther therapy continued under the physicians suryeillance is important. There are reports describing the cases in which methotrexate was continuous Iv administered orally at low doses for o ver 10 years (43 ). More tl1an 50% of patients treated with methotrexate take it for o ver three years, i.e. longer than any other drug modifying the course of the disease. Table 1 presents a review of selected papers discussing the duration of treatment of rheumatoid arthritis with methotrexate. The time of instituting methotrexate treatment in rheumatoid arthritis is also plays an important role. There are reports confirming the efficacy of the drug when it is administered before the formation of bone erosions. All investigators agree that methotrexate, irrespective of tl1e fact whether it is administered before or after the formation of irreversible bone lesions, inhibits the inflammatory process and slows dmvn the natural course of rheumatoid arthritis (30,31 ,42,44 ) .
Effect of Methotrexate on the Inflammatory Process
Methotrexate modifies the inflammatory process ( 16) whose characteristic feature in systemic connective tissue diseases is persistence despite administration of non-steroid anti-int1ammatory agents. The above phenomenon is due to the fact that with the current state of medical Imowledge it is impossible to eliminate the factor stimulating the inflammatory process from the human organism. The antiinfhmmatory effect of methotrexate and other drugs modi tying the course of the disease is not limited to inhibition of the released inflammation mediators, but results from the direct activity on the cells responsible fc)r immune response (15, 25, 38) . Activation of the immune response system is initiatcd at the moment of contact between the antigen and the cell capable of its presentation, after prior transfc)rmation of its molecule (26) . The cells functioning in this w ay are, first of all, macrophages, but the ability to present antigen is also demonstrated by A type synoviocytes, Y<lscular endothelial and dendritic cells.
Among numerous cytokines whose biological activity is already known, 11-1 , TNF-a, 11-6 and lI-8 playa particular role in infhmmations. In many research centres, the dtect of modulating drugs on the patients semm level of proinflammatory cytokines was investigatcd, as well as on their production, release to the medium and biological activity in blood cell cultures in vitro (26, 4 (26) . Drugs modifYing the course of rheumatoid arthritis, including methotrexate, act indirectly (due to their effect on T lymphocytes) and directly on the function of B lymphocytes. Normalisation of the elevated serum levels of M. type immunoglobulins (lgM) was observed in the patients treated with methotrexate, as well as lowering the titre of WaalerRose reaction. The above observations confirm that methotrexate inhibits the production of IgM and autoantibodies. Thus, it has been demonstrated that methotrexate used as the basic drug modifYing the course of rheumatoid arthritis suppresses both the development of acute inflammatory reaction and the function of tlle immwle system. It reduces the synthesis of B-4 leucotriene in the neutrophils (40) , lowers the level of neutral proteases, suppresses cellular immunity and exerts an anti-proliferative effect on endothelial cells.
Adverse Effects
Methotrexate is not free from side effects (1, 17) . The toxicity of the drug results from its antimetabolic effect 0n quickly proliferating cells in bone marrow, oral, gastric and intestinal mucous membranes. Nausea, vomiting and sitophobia are observed in 10% of patients (53) . Diarrhoea may occur after higher doses.
Methotrexate is a hepatotoxic drug (17, 21, 49) . The manifestations of severe toxicity can be abnormal values of hepatic enzyme levels. Prompt discontinuation of the treatment leads to normalisation of transaminase levels and reversibilitv of the adverse effects. Prolonged treatment may lead to fibrosis, and even cirrhosis of the liver. The risk of disease is low in the total population of patients treated with Pteridincs / Vol. 10 / No.3 small oral doses, but it appears to be higher in the groups of patients with coincident liver diseases, diabetes, psoriasis, kidney diseases, alcoholism, as well as in elderly patients (45, 47) . In the presence of such risk factors, instituting methotrexate therapy requires systematic control of hepatic enzyme values and, in case of any abnormalities, early discontinuation of the treatment.
A rare, but potentially fatal complication of methotrexate administration is interstitial pneumonia. Such a complication should be taken into consideration in a patient treated with the drug and complaining of dry cough, dyspnoea and fever. Soon after the first symptoms eosinophilia can develop. Chest X-rays reveal then bilateral diffuse infiltrations. It is believed that this complication usually occurs in patients treated with high doses. However, some investigators report it after the administration of low doses (7.5 -15 mg a week) used to treat rheumatoid arthritis (5,13). The predisposing factors are unknown. Because of this rare, but extremely dangerous for the patient, complication, the administration of the drug should be preceded in each patient by chest X-ray examination, and during follow-up visits the patient should be observed for the symptoms of lung damage such as cough and dyspnoea. There are also reports concerning the possibility of pneumonia caused by pneumocystis carini in patients treated with methotrexate (33, 41) .
Other adverse effects include anaemia, leukopenia and thrombocytopenia (7, 8, 12) . The risk factors for myelosuppression are: administration of drugs inactivating folic acid reductase, e.g. trimethoprim, folic acid deficiency and renal failure (47) . Severe m yelosuppression is rare after the doses reconunended for rheumatoid arthritis. The aim of monitoring of blood count parameters is to reduce the incidence and severity of bone marrow suppression and its complications, e.g. severe anaemia, sepsis and haemorrhages. Macrocytosis is also observed in patients receiving long-term methotrexate treatment. If it persists longer than 6 months, blood cell count parameters should be monitored systematically, because there is a risk of haematological complications.
Conunon, but mild side effect include inflammation of mucous membranes, alopecia, alimentary tract disorders. Such symptoms can be due to the deficiency of folic acid. They are treated, or prevented, by supplementation of folic acid in each patient treated with methotrexate (2). It should be stated that administration of low doses of folic acid (1 mg/ 24h) does not reduce the eHecti veness of methotrexate therapy (9) .
Methotrexate possesses teratogenic properties.
The administration of the dmg should be discontinued before the planned conception -in men at least three months earlier, in women one ovulation cycle. Methotrexate is not administered to pregnant and breast-feeding women.
There is a controversy concerning higher risk of malignancies in patients treated with methotrexate. Single reports indicate that there is a correlation between methotrexate therapy and development of lymphomas (3, 23, 39) . further studies are necessary to elucidate this problem. Nevertheless, each patient treated with methotrexate should be instmcted to consult the physician immediately in case of any enlargement of lymph nodes and the doctor managing the patient should perform a routine examination of lymph nodes during every fc)llow-up visit.
Safety of Methotrexate Treatment
Methotrexate is a folic acid antimetabolite, exhibiting potent cytostatic and immunosuppressive activity, which has been applied not only in the treatment of neoplasms, but also of diseases of immune aetiology (15 ) , such as rheumatoid arthritis. It is a drug characterised by certain toxicity fc)r humans, so before instituting methotrexate therapy some laboratory tests should be performed. During the period of treatment certain laboratory parameters should be monitored at minimum 4-8-week intervals. Preliminary investigations, indispensable before starting treatment with methotrexate in rheumatoid arthritis, include blood cell count (haematocrit, haemoglobin, leukocyte count \\'ith type percentages, platelet count), chest X-ray, AspAT, AlAT, albumin level, alkaline phosphatase, and in patients belonging to risk groups serological investigations for hepatitis virus B and hepatitis virus C. Therapy monitoring should include observation tc:)r symptoms of myelosuppression (fever, other symptoms of infection, susceptibility to bruising, bleeding) dyspnoea, nausea, vomiting, enlargement of lymph nodes. During methotrexate therapy it is also necessary to determine fllll blood cell count, AspAt, albumin and creatinine levels at 4-8-week intervals. The basic principles of monitoring methotrexate therapy in rheumatoid arthritis are presented in Table 2 .
Because of its teratogenic properties, methotrexate is contraindicated during pregnanc:~ Studies on animals and humans have demonstrated that there is a risk for the foetus, which undoubtedly exceeds potential benefits from the administration of the dmg. The dmg belongs to the X category according to FDA (Food and Drug Administration). Meth- otrexate causes spontaneous abortions in women, and in the foetus congenital defects including cleft palate and hydrocephalus. It is also contraindicated during the period of breast feeding, because small quantities present in milk can accumulate in the infants tissues. The drug also influences female fertility, although rarely it has distant effects, and 111 male patients it causes temporary oligospermia.
Prospects for the Future
Methotrexate is at present one of the main dmgs modifYing the course of rheumatoid arthritis, because its efficacy in slowing down the natural progress of the disease has been proved. In spite of numerous possible adverse effects which may occur during the treatment with methotrexate, it is commonly used by rheumatologists with appropriate surveillance and it will be used until new drugs, more effective than methotrexate and causing fewer adverse effects, are created.
